Aclaris Therapeutics gets 5.4% Frazier stake

Aclaris Therapeutics, Inc. (ACRS) received a Schedule 13G reporting that multiple Frazier Life Sciences-affiliated entities collectively report beneficial ownership positions in its common stock.

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. (ACRS) received a Schedule 13G reporting that multiple Frazier Life Sciences-affiliated entities collectively report beneficial ownership positions in its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 7,879,943 shares of common stock, representing 5.4% of the class based on 147,198,893 shares outstanding as of July 31, 2026.

Frazier Life Sciences XI, L.P. holds 86,910 shares (0.1%), and Frazier Life Sciences XII, L.P. holds 762,663 shares (0.5%), with related FHMLSP and FHMLS entities reporting corresponding shared voting and dispositive power. Voting and investment decisions for these funds are made by investment committees, and individual committee members are not attributed beneficial ownership.

Key Figures

Shares held by Frazier Life Sciences Public Fund, L.P.: 7,879,943 shares Ownership percentage of FLSPF: 5.4% Shares outstanding: 147,198,893 shares +5 more

8 metrics

Shares held by Frazier Life Sciences Public Fund, L.P. 7,879,943 shares Common Stock of Aclaris Therapeutics directly held by FLSPF

Ownership percentage of FLSPF 5.4% Percent of Aclaris common stock class held by Frazier Life Sciences Public Fund, L.P.

Shares outstanding 147,198,893 shares Aclaris common stock outstanding as of July 31, 2026

Shares held by Frazier Life Sciences XI, L.P. 86,910 shares Common Stock of Aclaris Therapeutics directly held by FLS XI

Ownership percentage of FLS XI 0.1% Percent of Aclaris common stock class held by Frazier Life Sciences XI, L.P.

Shares held by Frazier Life Sciences XII, L.P. 762,663 shares Common Stock of Aclaris Therapeutics directly held by FLS XII

Ownership percentage of FLS XII 0.5% Percent of Aclaris common stock class held by Frazier Life Sciences XII, L.P.

Shared voting power of FLSPF and affiliates 7,879,943 shares Shared voting and dispositive power reported for FLSPF-related entities

Key Terms

Schedule 13G, beneficial owner, shared voting power, shared dispositive power, +2 more

6 terms

Schedule 13G regulatory

"each Reporting Person's cover page to this Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficial owner regulatory

"shall not be construed as an admission that any Reporting Person is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

shared voting power financial

"Shared Voting Power 7,879,943.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 7,879,943.00"

CUSIP Number financial

"CUSIP Number(s): 00461U105"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

percent of class financial

"Percent of class: The information contained in row 11"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Schedule 13G filing disclose about ACRS ownership?

The filing disclosed that several Frazier Life Sciences-affiliated entities report beneficial ownership of Aclaris Therapeutics common stock, including Frazier Life Sciences Public Fund, L.P. with 7,879,943 shares, representing 5.4% of the outstanding common stock.

How many Aclaris (ACRS) shares does Frazier Life Sciences Public Fund, L.P. hold?

Frazier Life Sciences Public Fund, L.P. directly holds 7,879,943 shares of Aclaris Therapeutics common stock. This stake represents 5.4% of the class, based on 147,198,893 shares outstanding as of July 31, 2026.

What smaller positions do Frazier Life Sciences XI and XII hold in ACRS?

Frazier Life Sciences XI, L.P. holds 86,910 shares of Aclaris common stock, or 0.1% of the class. Frazier Life Sciences XII, L.P. holds 762,663 shares, or 0.5% of the class, using the same 147,198,893-share outstanding base.

What are the reported voting and dispositive powers over Aclaris (ACRS) shares?

The Frazier Life Sciences funds report 0 shares with sole voting or dispositive power and instead report shared voting and shared dispositive power over the Aclaris shares held by each fund, as shown on their respective cover pages.

How was the ownership percentage for ACRS calculated in the Schedule 13G?

Each reported percentage was calculated using 147,198,893 shares of Aclaris common stock outstanding as of July 31, 2026, as stated in Aclaris Therapeutics’ Quarterly Report on Form 10-Q filed on August 6, 2026.

Who signed the Schedule 13G on behalf of the Frazier entities for ACRS?

The Schedule 13G was signed by Jennifer Martin, identified as CFO of the various FHMLSP and FHMLS LLC general partners of the Frazier Life Sciences funds, with signatures dated September 21, 2026 for each reporting entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:10 PM Accepted by SEC EDGAR 09/21/2026 - 04:09 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ACLARIS THERAPEUTICS, INC.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

00461U105

(CUSIP Number)

09/14/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,879,943.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,879,943.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,879,943.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLSP, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,879,943.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,879,943.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,879,943.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLSP, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,879,943.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,879,943.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,879,943.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

Frazier Life Sciences XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 86,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 86,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

86,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLS XI, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 86,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 86,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

86,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLS XI, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 86,910.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 86,910.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

86,910.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.1 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

Frazier Life Sciences XII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 762,663.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 762,663.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

762,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLS XII, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 762,663.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 762,663.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

762,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

CUSIP Number(s): 00461U105

1

Names of Reporting Persons

FHMLS XII, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 762,663.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 762,663.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

762,663.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 147,198,893 shares of Common Stock outstanding on July 31, 2026, as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ACLARIS THERAPEUTICS, INC.
(b)	Address of issuer's principal executive offices: 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Item 2.
(a)	Name of person filing: The entities and persons filing this statement (collectively, the "Reporting Persons") are: Frazier Life Sciences Public Fund, L.P. ("FLSPF") FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences XI, L.P. ("FLS XI") FHMLS XI, L.P. FHMLS XI, L.L.C. Frazier Life Sciences XII, L.P. ("FLS XII") FHMLS XII, L.P. FHMLS XII, L.L.C.
(b)	Address or principal business office or, if none, residence: The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304
(c)	Citizenship: The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.
(d)	Title of class of securities: Common Stock, $0.00001 par value
(e)	CUSIP Number(s): 00461U105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. FLSPF directly holds 7,879,943 shares of Common Stock. FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF. FLS XI directly holds 86,910 shares of Common Stock. FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI. FLS XII directly holds 762,663 shares of Common Stock. FHMLS XII, L.P. is the general partner of FLS XII and the general partner of FHMLS XII, L.P. is FHMLS XII, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XII. Except as specifically stated herein, the filing of this Schedule 13G shall not be construed as an admission that any Reporting Person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person.
(b)	Percent of class: The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences Public Fund, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Date:	09/21/2026

FHMLSP, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.
Date:	09/21/2026

FHMLSP, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLSP, L.L.C.
Date:	09/21/2026

Frazier Life Sciences XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.
Date:	09/21/2026

FHMLS XI, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.
Date:	09/21/2026

FHMLS XI, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XI, L.L.C.
Date:	09/21/2026

Frazier Life Sciences XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P.
Date:	09/21/2026

FHMLS XII, L.P.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C., GP of FHMLS XII, L.P.
Date:	09/21/2026

FHMLS XII, L.L.C.

Signature:	/s/ Jennifer Martin
Name/Title:	By Jennifer Martin, CFO of FHMLS XII, L.L.C.
Date:	09/21/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement